Price T Rowe Associates Inc Autolus Therapeutics PLC Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,939,241 shares of AUTL stock, worth $5.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,939,241
Previous 3,841,502
23.49%
Holding current value
$5.26 Million
Previous $13.9 Million
50.46%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AUTL
# of Institutions
112Shares Held
156MCall Options Held
0Put Options Held
116K-
Wellington Management Group LLP Boston, MA25.3MShares$45.4 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$36.7 Million0.24% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$29.8 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT14.2MShares$25.5 Million1.47% of portfolio
-
Avoro Capital Advisors LLC New York, NY9.91MShares$17.7 Million0.34% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $163M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...